Stock Analiz

Lexicon Pharmaceuticals, Inc. LXRX

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.79Market cap $797M
Open the interactive analysis →

Lexicon Pharmaceuticals, Inc. (LXRX) is a healthcare company listed in the US with a market value of about $797M. In the twelve months to September 30, 2026 it had revenue of $39M and net income of -$62M, a net margin of -161.8%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 16% a year, a 5-year average ROIC of -55%.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $23M in 2014 to $50M in 2025, growth of about 7.3% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 119% over three years (dilution for shareholders). It spends 123% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S20.7
P/B4.9
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-6.2%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)60.2%
Revenue growth (5 yrs, per year)15.7%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-23649.4%
ROIC (5-yr avg.)-54.9%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$39M$50M$31M$1M$139000$298000$24M$322M$63M$92M$79M
Net income-$62M-$50M-$200M-$177M-$102M-$88M-$59M$130M-$121M-$123M-$131M
Free cash flow-$49M-$68M-$180M-$162M-$90M-$88M-$143M$114M-$149M-$186M-$176M
EPS (diluted)$-0.14$-0.14$-0.63$-0.80$-0.62$-0.60$-0.53$1.16$-1.14$-1.17$-1.27
Net margin-161.8%-101.1%-644.8%-14710.9%-73341.0%-29449.0%-244.1%40.4%-190.7%-134.1%-165.9%
ROIC—-22.8%-61.8%-68.1%-46.2%-75.9%-22.4%30.5%-36.5%-32.3%-47.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 6 analysts is $4.51, 152% above the current price; targets range from $1.69 to $8.00; the consensus rating is “Buy”; expected EPS is $-0.16 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Lexicon Pharmaceuticals pay a dividend?

Not currently.

Is Lexicon Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Lexicon Pharmaceuticals scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.